EPS for Houlihan Lokey, Inc. (HLI) Expected At $0.53; Yield10 Bioscience (YTEN) Shorts Raised By 25%

January 25, 2018 - By Peter Erickson

Analysts expect Houlihan Lokey, Inc. (NYSE:HLI) to report $0.53 EPS on February, 7.They anticipate $0.04 EPS change or 7.02% from last quarter’s $0.57 EPS. HLI’s profit would be $34.90 million giving it 24.32 P/E if the $0.53 EPS is correct. After having $0.56 EPS previously, Houlihan Lokey, Inc.’s analysts see -5.36% EPS growth. The stock increased 0.88% or $0.45 during the last trading session, reaching $51.55. About 139,282 shares traded. Houlihan Lokey, Inc. (NYSE:HLI) has risen 49.19% since January 25, 2017 and is uptrending. It has outperformed by 32.49% the S&P500.

Yield10 Bioscience Incorporated (NASDAQ:YTEN) had an increase of 25% in short interest. YTEN’s SI was 77,500 shares in January as released by FINRA. Its up 25% from 62,000 shares previously. With 18,700 avg volume, 4 days are for Yield10 Bioscience Incorporated (NASDAQ:YTEN)’s short sellers to cover YTEN’s short positions. The stock decreased 4.42% or $0.08 during the last trading session, reaching $1.73. About 299,195 shares traded. Yield10 Bioscience, Inc. (NASDAQ:YTEN) has 0.00% since January 25, 2017 and is . It has underperformed by 16.70% the S&P500.

Yield10 Bioscience, Inc., an agricultural bioscience company, engages in developing disruptive technologies for enhancing crop yield in the United States. The company has market cap of $14.85 million. It is developing various yield traits using proprietary advanced biotechnology trait gene discovery platforms. It currently has negative earnings. The firm was formerly known as Metabolix, Inc. and changed its name to Yield10 Bioscience, Inc. in January 2017.

Among 8 analysts covering Houlihan Lokey (NYSE:HLI), 5 have Buy rating, 0 Sell and 3 Hold. Therefore 63% are positive. Houlihan Lokey had 17 analyst reports since September 8, 2015 according to SRatingsIntel. The company was initiated on Tuesday, September 8 by JMP Securities. The rating was maintained by UBS with “Buy” on Wednesday, July 26. The stock of Houlihan Lokey, Inc. (NYSE:HLI) has “Neutral” rating given on Thursday, May 11 by Bank of America. The rating was initiated by Goldman Sachs on Tuesday, September 8 with “Neutral”. The stock of Houlihan Lokey, Inc. (NYSE:HLI) earned “Buy” rating by Bank of America on Tuesday, September 8. The stock has “Buy” rating by Keefe Bruyette & Woods on Sunday, August 27. Bank of America maintained Houlihan Lokey, Inc. (NYSE:HLI) on Wednesday, October 25 with “Neutral” rating. The company was initiated on Tuesday, September 8 by Sandler O’Neill. Keefe Bruyette & Woods maintained Houlihan Lokey, Inc. (NYSE:HLI) on Wednesday, January 10 with “Buy” rating. The firm earned “Outperform” rating on Tuesday, September 8 by Keefe Bruyette & Woods.

Houlihan Lokey, Inc., an investment banking company, provides mergers and acquisitions , financings, financial restructurings, and financial advisory services in the United States, Canada, Europe, Asia, Australia, the Middle East, Latin America, and Africa. The company has market cap of $3.40 billion. The Company’s Corporate Finance segment offers general financial advisory services on M&A and capital markets offerings; advises public and private institutions on buy-side and sell-side transactions, leveraged loans, private mezzanine debt, high-yield debt, initial public offerings, follow-ons, convertibles, equity private placements, private equity, and liability management transactions; and advises financial sponsors on various transactions. It has a 24.43 P/E ratio. This segment also provides financing solutions and capital-raising advisory services for publicly-held and multinational firms, financial sponsors, and privately-held companies.